Abstract
Alcohol- and formalin-fixed, paraffin-embedded samples of 71 brain tumors (35 gliomas, 22 metastatic carcinomas, 8 meningiomas and 6 other tumors) were investigated by immunocytochemistry with three different monoclonal antibodies against proliferating cell nuclear antigen (PCNA)/cyclin (19A2; 19F4; PC10). PC10 was found to work best; it is applicable to both alcohol- and formalin-fixed tumor samples. PCNA labeling indices (LIs) were compared in the same tumors with LIs obtained by Ki-67 immunostaining of frozen sections and by in vitro incubation with bromodeoxyuridine (BrdUrd); in the latter preparations, BrdUrd LIs could be compared with PCNA LIs in the very same areas of serial sections. In gliomas, PCNA LIs were 0.7–80.2% (mean 31.7%), in metastases 0–76.0% (mean 47.8%), and in meningiomas 0–53.0% (mean 19.3%). In general, PCNA LIs were highly significantly correlated with Ki-67 LIs (P=0.0002) and BrdUrd LIs (P=0.0001). However, when tumor subgroups are considered, only gliomas show a significant correlation with Ki-67 and BrdUrd LIs. Despite this statistical correlation, PCNA expression was out of proportion to proliferation indices as determined by both other methods in almost one third of all brain tumors. Immunocytochemistry for PCNA produces a broad spectrum of staining intensity of labeled nuclei, whose number is dependent upon the sensitivity of the immunocytochemical technique used. Thus, inter-oberserver and inter-laboratory variabilities in PCNA LI determination may occur. Overlapping of PCNA LIs between tumor subgroups of varying malignancy further limits the informational value for the individual case. In some classic meningiomas, high PCNA scores do not reflect the proliferative activity of the tumor, as Ki-67 and BrdUrd LIs are very low in these cases. We conclude that PCNA immunolabeling is of limited value in the individual tumor, mainly due to overexpression in many tumors, and at present cannot be recommended to replace Ki-67 and/or BrdUrd labeling methods for routine determination of proliferative activity in human tumor specimens.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Allegranza A, Girlando S, Arrigoni GL, Veronese S, Mauri FA, Gambacorta M, Pollo B, Dalla Palma P, Barbareschi M (1991) Proliferating cell nuclear antigen expression in central nervous system neoplasms. Virchows Arch [A] 419: 417–423
Bauer GA, Burgers PM (1988) The yeast analog of mammalian cyclin/proliferating cell nuclear antigen interacts with mammalian DNA polymerase delta. Proc Natl Acad Sci USA 85: 7506–7510
Benjamin DR, Gown AM (1991) Aberrant cytoplasmic expression of proliferating cell nuclear antigen in Hodgkin's disease. Am J Surg Pathol 15: 764–768
Bravo R (1986) Synthesis of the nuclear protein cyclin (PCNA) and its relationship with DNA replication. Exp Cell Res 163: 287–293
Bravo R, Macdonald-Bravo H (1987) Existance of two populations of cyclin/PCNA during the cell cycle: association with DNA replication sites. J Cell Biol 105: 1549–1554
Bravo R, Frank R, Blundell PA, MacDonald-Bravo H (1987) Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ. Nature 326: 515–517
Burns DK, Mickey BE, Bigio EH, White CL (1992) Proliferating cell nuclear antigen (PCNA) expression in human gliomas and meningiomas (abstract). J Neuropathol Exp Neurol 51: 362
Celis JE, Celis A (1985) Cell cycle-dependent variation in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci USA 82: 3262–3266
Dalla Palma P, Barbareschi M, Perrone G, Mauri FA, Girlando S, Leonardi E, Togni R, Boi S, Dvornik G (1991) PCNA and Ki-67 expression in breast carcinomas (abstract). Pathol Res Pract 187: 674
Dervan PA, Magee HM, Buckley C, Carney DN (1992) Proliferating cell nuclear antigen counts in formalin-fixed paraffin-embedded tissue correlate with Ki-67 in fresh tissue. Am J Clin Pathol 97 [Suppl 1]: S21-S28
Dierendonk JH van, Wijsman JH, Keijzer R, van de Velde CJH, Cornelisse CJ (1991) Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Am J Pathol 138: 1165–1172
Galand P, Degraef C (1989) Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labeling for marking S phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet 22: 383–392
Garcia RL, Coltrera MD, Gown AM (1989) Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Am J Pathol 134: 733–739
Golick ML, Rice M (1992) Optimum staining of PCNA in paraffin sections is dependent on fixation, dyring, and intensification. J Histotechnol 15: 39–41
Hall PA, Levison DA, Woods AL, Yu CC-W, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Campleijohn R, Dover R, Waseem NH, Lane DP (1990) Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasmas. J Pathol 162: 285–294
Hsu S-M, Raine L, Fanger H (1981) Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577–580
Jaskulski D, DeRiel JK, Mercer WE, Calabretta B, Baserga R (1988) Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA Cyclin. Science 240: 1544–1546
Kurki P, Lotz M, Ogata K, Tan EM (1987) Proliferating cell nuclear antigen (PCNA)/cyclin in activated human T lymphocytes. J Immunol 138: 4114–4120
Kurki P, Ogata K, Tan EM (1988) Monoclonal antibodies to proliferating cell nuclear antigen (PCNA)/cyclin as probes for proliferating cells by immunofluorescence microscopy and flow cytometry. J Immunol Methods 109: 49–59
Louis DN, Edgerton S, Thor AD, Hedley-Whyte ET (1991) Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol 81: 675–679
Maier H, Morimura T, Öfner D, Hallbrucker C, Budka H (1990) Argyrophilic nucleolar organizer region proteins (AgNORs) in human brain tumors: relations with malignancy and proliferation indices. Acta Neuropathol 80: 156–162
Maier H, Kitz K, Öfner D, Hittmair A, Budka H (1992) Classical, atypical and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg 77: 616–623
Mathews MB, Bernstein RM, Franza BR Jr, Garrels GI (1984) Identity of the proliferating cell nuclear antigens and cyclin. Nature 309: 374–376
Mauri FA, Allegranza A, Barbareschi M, Girlando S, Pollo B, Palma P, Scampinis S (1991) PCNA expression in pleomorphic astrocytomas and in other glial neoplasms (abstract). Pathol Res Pract 187: 723
Morimura T, Kitz K, Budka H (1989) In situ analysis of cell kinetics in brain tumors. Acta Neuropathol 77: 276–282
Morimura T, Kitz K, Stein H, Budka H (1991) Determination of proliferative activities in human brain tumor specimens: a comparison of three methods. J Neuro-Oncol 10: 1–11
Morris GF, Mathews MB (1989) Regulation of proliferating cell nuclear antigen during cell cycle. J Biol Chem 264: 13 856–13 864
Ogata K, Kurki P, Celis J, Nakamura RM, Tan EM (1987) Monoclonal antibodies to a nuclear protein (PCNA, cyclin) associated with DNA replication. Exp Cell Res 168: 475–486
Pelosi G, Zamboni G, Colombari R, Castelli P, Pea M, Bresaola E, Boneti F, Iannucci A (1991) Immunohistochemical detection of proliferating cell nuclear antigen (PCNA) in P.E.T. (pancreatic endocrine tumors) (abstract). Pathol Res Pract 198: 744
Prelich G, Kostura M, Marshak DR, Mathews MB, Stillman B (1987) The cell-cycle regulated proliferating cell nuclear antigen is required for SV40 DNA replication in vitro. Nature 326: 471–475
Prelich G, Tan C-K, Kostura M, Mathews MB, So AG, Downey KM, Stillman B (1987) Functional identity of proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein. Nature 326: 517–520
Robbins BA, de la Vega D, Ogata K, Tan EM, Nakamura RM (1987) Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies. Arch Pathol Lab Med 111: 841–845
Smetana K, Gyorkey F, Chan P-K, Tan E, Busch H (1983) Proliferating cell nuclear antigen (PCNA) and human malignant tumor nucleolar antigens (HMTNA) in nucleoli of human hematological malignancies. Blut 46: 133–141
Tan CK, Sullivan K, Li XY, Tan EM, Downey KM, So AG (1987) Autoantibody to the proliferating cell nuclear antigen neutralizes the activity of the auxiliary protein for polymerase delta. Nucleic Acids Res 15: 9299–9308
Waseem NH, Lane DP (1990) Monoclonal antibody analysis of proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci 96: 121–129
Author information
Authors and Affiliations
Additional information
Supported in part by a grant from the Oncology Commission, Medical Faculty, University of Vienna
Rights and permissions
About this article
Cite this article
Khoshyomn, S., Maier, H., Morimura, T. et al. Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens. Acta Neuropathol 86, 582–589 (1993). https://doi.org/10.1007/BF00294296
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00294296